The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 15, 2020

Filed:

Dec. 12, 2019
Applicant:

Astellas Pharma Inc., Tokyo, JP;

Inventors:

Kazuyuki Kuramoto, Tokyo, JP;

Michinori Akaiwa, Tokyo, JP;

Tomoaki Abe, Tokyo, JP;

Takanobu Araki, Tokyo, JP;

Susumu Yamaki, Tokyo, JP;

Shigeki Kunikawa, Tokyo, JP;

Tomoyoshi Imaizumi, Tokyo, JP;

Takahiro Nigawara, Tokyo, JP;

Keisuke Arakawa, Tokyo, JP;

Itsuro Shimada, Tokyo, JP;

Masashi Shimazaki, Tokyo, JP;

Yoshiki Satake, Tokyo, JP;

Kazushi Watanabe, Tokyo, JP;

Takanori Koike, Tokyo, JP;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 471/10 (2006.01); A61K 31/517 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07D 471/10 (2013.01); A61K 31/517 (2013.01); A61P 35/00 (2018.01);
Abstract

[Problem] Provided is a compound which is useful as an active ingredient of a pharmaceutical composition for treating lung cancer. [Means for Solution] The present inventors have studied a compound useful as an active ingredient of a pharmaceutical composition for treating lung cancer, and as a result, it was found that a quinazoline compound has an excellent G12C mutation KRAS inhibitory activity, and which can be used as a therapeutic agent for lung cancer, and thereby the present invention has been completed. The quinazoline compound of the present invention and a salt thereof may be used as the therapeutic agent for lung cancer.


Find Patent Forward Citations

Loading…